The Perioperative Application of Tranexamic Acid

Carsten Perka; Christian von Heymann; Heiko Lier; Lutz Kaufner; Sascha Treskatsch

doi:10.1055/a-2055-8178

Zeitschrift für Orthopädie und Unfallchirurgie, Inhaltsverzeichnis

Z Orthop Unfall 2023; 161(05): 532-537
DOI: 10.1055/a-2055-8178

Review

The Perioperative Application of Tranexamic Acid

Recommendation of the Working Group Endoprosthetics in Cooperation with an Expert Group of the German Society for Anesthesiology and Intensive Care Medicine Update February 2023 Artikel in mehreren Sprachen: English | deutsch

Carsten Perka

¹Klinik für Orthopädie, Centrum für Muskuloskeletale Chirurgie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland (Ringgold ID: RIN14903)

,

Christian von Heymann

²Klinik für Anästhesie, Intensivmedizin, Notfallmedizin und Schmerztherapie, Vivantes Klinikum im Friedrichshain, Berlin, Berlin, Deutschland

,

Heiko Lier

³Klinik für Anästhesiologie und Operative Intensivmedizin, Medizinische Fakultät und Uniklinik Köln, Köln, Deutschland

,

Lutz Kaufner

⁴Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin, Charité ‒ Universitätsmedizin Berlin, Berlin, Deutschland (Ringgold ID: RIN14903)

,

Sascha Treskatsch

⁴Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin, Charité ‒ Universitätsmedizin Berlin, Berlin, Deutschland (Ringgold ID: RIN14903)

› Institutsangaben

Abstract

The application of tranexamic acid (TXA) during endoprosthetic surgical procedures has significantly increased in recent years. Due its ability to reduce perioperative blood loss and avert the need for blood transfusions as well as wound drainage, TXA is becoming part of a ‘standard practice’. However, TXA is currently not approved for the application during endoprosthetic procedures and therefore, a benefit-risk analysis should always be conducted. Prophylactic administration of TXA without prior patient consent is only justified if fibrinolytic bleeding is expected and there are no contraindications or relevant risk factors for thromboembolic complications. Respectively, no patient consent is required when a therapeutic dose of TXA is administered in the context of fibrinolytic bleeding. The following guidelines provide updated recommendations based on the current state of knowledge on TXA optimal timing, routes of administration and dosing regimen.

Keywords

tranexamic acid - fibrinolysis - hyperfibrinolysis - blood loss

Volltext

Referenzen

References
1 Kozek-Langenecker SA, Ahmed AB, Afshari A. et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol 2017; 34: 332-395
2 Cardone D, Klein AA. Perioperative blood conservation. Eur J Anaesthesiol 2009; 26: 722-729
3 Coetzee MJ. The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia. Haemophilia 2007; 13: 443-444
4 Dhir A. Antifibrinolytics in cardiac surgery. Ann Card Anaesth 2013; 16: 117-125
5 Massicotte L, Denault AY, Beaulieu D. et al. Aprotinin versus tranexamic acid during liver transplantation: impact on blood product requirements and survival. Transplantation 2011; 91: 1273-1278
6 Myles PS, Smith JA, Forbes A. et al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med 2017; 376: 136-148
7 Wong J, Abrishami A, El Beheiry H. et al. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am 2010; 92: 2503-2513
8 Charoencholvanich K, Siriwattanasakul P. Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial. Clin Orthop Relat Res 2011; 469: 2874-2880
9 Camarasa MA, Ollé G, Serra-Prat M. et al. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial. Br J Anaesth 2006; 96: 576-582
10 MacGillivray RG, Tarabichi SB, Hawari MF. et al. Tranexamic acid to reduce blood loss after bilateral total knee arthroplasty: a prospective, randomized double blind study. J Arthroplasty 2011; 26: 24-28
11 Benoni G, Fredin H, Knebel R. et al. Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations. Acta Orthop Scand 2001; 72: 442-448
12 Johansson T, Pettersson LG, Lisander B. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. Acta Orthop 2005; 76: 314-319
13 Husted H, Blond L, Sonne-Holm S. et al. Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients. Acta Orthop Scand 2003; 74: 665-669
14 Poeran J, Rasul R, Suzuki S. et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ 2014; 349: g4829
15 Alshryda S, Sukeik M, Sarda P. et al. A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement. Bone Joint J 2014; 96-B: 1005-1015
16 Huang F, Wu D, Ma G. et al. The use of tranexamic acid to reduce blood loss and transfusion in major orthopedic surgery: a meta-analysis. J Surg Res 2014; 186: 318-327
17 Poeran J, Chan JJ, Zubizarreta N. et al. Safety of Tranexamic Acid in Hip and Knee Arthroplasty in High-risk Patients. Anesthesiology 2021; 135: 57-68
18 Lazic I, Haug AT, von Eisenhart-Rothe R. Perioperativer Einsatz der Tranexamsäure in der Endoprothetik. Knie Journal 2020; 2: 3-8
19 Myers SP, Kutcher ME, Rosengart MR. et al. Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. J Trauma Acute Care Surg 2019; 86: 20-27
20 HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020; 395: 1927-1936
21 [Anonym]. S3-Leitlinie Prophylaxe der venösen Thromboembolie (VTE). Zugriff am 09. Mai 2023 unter: https://register.awmf.org/assets/guidelines/003–001l_S3_VTE-Prophylaxe_2015–10-abgelaufen_01.pdf
22 Keller K, Hobohm L, Barco S. et al. Venous thromboembolism in patients hospitalized for hip joint replacement surgery. Thromb Res 2020; 190: 1-7
23 Taeuber I, Weibel S, Herrmann E. et al. Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality. JAMA Surgery 2021; 156: e210884
24 Mi B, Liu G, Lv H. et al. Is combined use of intravenous and intraarticular tranexamic acid superior to intravenous or intraarticular tranexamic acid alone in total knee arthroplasty? A meta-analysis of randomized controlled trials. J Orthop Surg Res 2017; 12: 61
25 Yi Z, Bin S, Jing Y. et al. Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial of Intravenous Combined with Topical Versus Single-Dose Intravenous Administration. J Bone Joint Surg Am 2016; 98: 983-991
26 Sukeik M, Alshryda S, Haddad FS. et al. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 2011; 93: 39-46
27 Yang ZG, Chen WP, Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am 2012; 94: 1153-1159
28 Sabbag OD, Abdel MP, Amundson AW. et al. Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study. J Arthroplasty 2017; 32: S246-S250
29 Shakur H, Roberts I, Bautista R. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32
30 CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019; 394: 1713-1723
31 WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389: 2105-2116
32 Holcomb JB, Sauaia A, Cardenas JC. Tranexamic Acid and Safety in the Right Patient. JAMA Surg 2021; e210929
33 Devereaux PJ, Marcucci M, Painter TW. et al. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N Engl J Med 2022; 386: 1986-1997
34 Spahn DR, Bouillon B, Cerny V. et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 2019; 23: 98
35 Cotton BA, Harvin JA, Kostousouv V. et al. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg 2012; 73: 365-370
36 Ives C, Inaba K, Branco BC. et al. Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma. J Am Coll Surg 2012; 215: 496-502
37 Marinho DS. Perioperative hyperfibrinolysis – physiology and pathophysiology. Braz J Anesthesiol 2021; 71: 65-75
38 Groene P, Sappel SR, Saller T. et al. Functional testing of tranexamic acid effects in patients undergoing elective orthopaedic surgery. J Thromb Thrombolysis 2021; 51: 989-996
39 Blanie A, Bellamy L, Rhayem Y. et al. Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res 2013; 131: e6-e11
40 Eriksson BI, Hultman E, Martinell S. et al. Regional fibrinolysis following total hip replacement. Thromb Res 1991; 62: 441-447
41 Lier H, Kammerer T, Knapp J. et al. [Tranexamic acid and arthroplasty: between off-label use and evidence-based medicine]. Anaesthesist 2021; 70: 614-615
42 Nelson JT, Coleman JR, Carmichael H. et al. High Rate of Fibrinolytic Shutdown and Venous Thromboembolism in Patients With Severe Pelvic Fracture. J Surg Res 2020; 246: 182-189
43 David JS, Lambert A, Bouzat P. et al. Fibrinolytic shutdown diagnosed with rotational thromboelastometry represents a moderate form of coagulopathy associated with transfusion requirement and mortality: A retrospective analysis. Eur J Anaesthesiol 2020; 37: 170-179
44 Raveh Y, Souki F, Livingstone J. et al. Fibrinolytic Shutdown Is Associated With Intraoperative Thrombosis and Hemorrhage During Visceral Transplant. Semin Cardiothorac Vasc Anesth 2019; 23: 300-308
45 Matsumoto H, Ishimaru K, Kikuchi S. et al. Perioperative coagulofibrinolytic responses in colorectal surgery patients without chemical thromboprophylaxis: a retrospective observational study. Surg Today 2022; 52: 904-913
46 Moore HB, Moore EE, Liras IN. et al. Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients. J Am Coll Surg 2016; 222: 347-355
47 Meizoso JP, Dudaryk R, Mulder MB. et al. Increased risk of fibrinolysis shutdown among severely injured trauma patients receiving tranexamic acid. J Trauma Acute Care Surg 2018; 84: 426-432
48 Nicolau-Raducu R, Beduschi T, Vianna R. et al. Fibrinolysis Shutdown Is Associated With Thrombotic and Hemorrhagic Complications and Poorer Outcomes After Liver Transplantation. Liver Transpl 2019; 25: 380-387
49 Moore HB, Moore EE, Huebner BR. et al. Fibrinolysis shutdown is associated with a fivefold increase in mortality in trauma patients lacking hypersensitivity to tissue plasminogen activator. J Trauma Acute Care Surg 2017; 83: 1014-1022
50 Sidelmann JJ, Gram JB, Godtfredsen ACM. et al. Orthognathic Surgery-Induced Fibrinolytic Shutdown Is Amplified by Tranexamic Acid. J Oral Maxillofac Surg 2020; 78: 1183-1189
51 Kammerer T, Groene P, Sappel SR. et al. Functional Testing for Tranexamic Acid Duration of Action Using Modified Viscoelastometry. Transfus Med Hemother 2021; 48: 109-117
52 Pekrul I, Schachtner T, Zwissler B. et al. Tranexamic acid for bleeding prophylaxis in orthopedic surgery and trauma-standard or customized therapy?. Anaesthesist 2021; 70: 515-521
53 Fillingham YA, Ramkumar DB, Jevsevar DS. et al. Tranexamic Acid Use in Total Joint Arthroplasty: The Clinical Practice Guidelines Endorsed by the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society. J Arthroplasty 2018; 33: 3065-3069
54 Yamasaki S, Masuhara K, Fuji T. Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases. Int Orthop 2004; 28: 69-73
55 Rajesparan K, Biant LC, Ahmad M. et al. The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. J Bone Joint Surg Br 2009; 91: 776-783
56 Ekback G, Axelsson K, Ryttberg L. et al. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg 2000; 91: 1124-1130
57 Singh J, Ballal MS, Mitchell P. et al. Effects of tranexamic acid on blood loss during total hip arthroplasty. J Orthop Surg (Hong Kong) 2010; 18: 282-286
58 Garneti N, Field J. Bone bleeding during total hip arthroplasty after administration of tranexamic acid. J Arthroplasty 2004; 19: 488-492
59 Claeys MA, Vermeersch N, Haentjens P. Reduction of blood loss with tranexamic acid in primary total hip replacement surgery. Acta Chir Belg 2007; 107: 397-401
60 Wang C, Kang P, Ma J. et al. Single-dose tranexamic acid for reducing bleeding and transfusions in total hip arthroplasty: A double-blind, randomized controlled trial of different doses. Thromb Res 2016; 141: 119-123
61 Nielsen CS, Jans O, Orsnes T. et al. Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial. J Bone Joint Surg Am 2016; 98: 835-841
62 Lin C, Qi Y, Jie L. et al. Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: A meta-analysis. Medicine (Baltimore) 2016; 95: e5344
63 Eikebrokk TA, Vassmyr BS, Ausen K. et al. Cytotoxicity and effect on wound re-epithelialization after topical administration of tranexamic acid. BJS Open 2019; 3: 840-851
64 Wang N, Xiong X, Xu L. et al. Transfusions and cost-benefit of oral versus intravenous tranexamic acid in primary total hip arthroplasty: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019; 98: e15279
65 Sun C, Zhang X, Chen L. et al. Comparison of oral versus intravenous tranexamic acid in total knee and hip arthroplasty: A GRADE analysis and meta-analysis. Medicine 2020; 99: e22999
66 Eriksson O, Kjellman H, Pilbrant A. et al. Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers. Eur J Clin Pharmacol 1974; 7: 375-380
67 DeFrancesco CJ, Reichel JF, Gbaje E. et al. A randomised non-inferiority trial comparing the effectiveness of oral versus intravenous tranexamic acid in primary total hip and knee arthroplasty. Br J Anaesth 2023; 130: 234-241
68 Samama CM, Afshari A. ESA VTE Guideline Task Force. European guidelines on perioperative venous thromboembolism prophylaxis. Eur J Anaesthesiol 2018; 35: 73-76
69 Petersen PB, Kehlet H, Jorgensen CC. et al. Safety of In-Hospital Only Thromboprophylaxis after Fast-Track Total Hip and Knee Arthroplasty: A Prospective Follow-Up Study in 17,582 Procedures. Thromb Haemost 2018; 118: 2152-2161
70 Kastelik J, Fuchs M, Kramer M. et al. Local infiltration anaesthesia versus sciatic nerve and adductor canal block for fast-track knee arthroplasty: A randomised controlled clinical trial. Eur J Anaesthesiol 2019; 36: 255-263